Bolivia Registro Sanitario: Nature, DI and DN Numbering, and 5-Year Validity

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The Bolivian sanitary registration (Registro Sanitario) is a product-level authorization document: it is valid for 5 years from the date of issuance (Section 3.1.5 of the manual), imported devices carry a registration number with the DI code prefix, and domestically manufactured devices carry the DN prefix. Three hard constraints define the boundary of its effect. First, the registration number must be placed in a prominent position on the packaging, by printing, an indelible ink stamp, or a label (Section 5.7.1). Second, the certificate-holding enterprise must complete its annual review before December 31 of each year (Section 5.7.2). Third, ownership of the registration does not necessarily rest with the party that handles the procedure (Section 3.2.1). GRZAN cautions that reading the sanitary registration as simply a certificate valid for five years overlooks two continuing obligations embedded in it, and these continuing obligations are where importers, distributors, and manufacturers most often lose alignment over the life of the product.

The product-level nature of the registration also explains the arithmetic of a Bolivian device program. One certificate covers one group, so a portfolio is represented by a portfolio of certificates, each with its own five-year expiry, its own prefix, and its own label obligations. Every certificate is a separate object to track, and every renewal is a separate decision about whether the product remains on the market. This is the practical reason why the certificate calendar recommended below is not an optional housekeeping tool but the primary control instrument of a Bolivian registration portfolio, and why it should record not only expiry dates but also the entity in whose name each certificate is held.

2. Legal basis

InstrumentNumber / referencePublication dateProvision
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 3.1.5
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 3.2.1
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 5.7.1
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 5.7.2

3. Expert insights

Insight one: the 30-working-day issuance timeline is the clock for a clean dossier, not the end-to-end cycle. The wording of Section 3.1.5 is issuance within 30 working days after submission. Legalization and additional certificates, translation into Spanish, and rounds of responses to observations all stack outside this clock. A company that schedules production and launch on the basis of 30 working days will almost certainly miss its dates, so the observation round should be treated as a planning assumption from the start rather than as an exception.

Insight two: the DI and DN prefixes are supply chain information, not merely a coding rule. Tender committees, purchasers, and competitors can all read the structure of the supply chain behind a product from the prefix of its registration number. When designing the channel structure, a company should manage the prefix as publicly readable commercial information, because it signals whether the product is locally manufactured or imported, and therefore which levers of pricing, lead time, and local content apply in public procurement.

Insight three: the annual review and the five-year renewal are two independent obligations. The annual review under Section 5.7.2 (before December 31 of each year) concerns the enterprise; the five-year renewal concerns the product. Lapse of the enterprise certificate has a knock-on effect on every registration held under it, which makes the annual review status of the certificate holder a priority item in importer due diligence, checked before signing and re-checked at least once a year.

Insight four: the ownership question of Section 3.2.1 is a contract question first. The manual’s acknowledgment that the registration does not necessarily belong to the party that handles the procedure means the real protection for a manufacturer lies in the agreement with the local holder. A well-drafted clause covers what happens to the registration when the distribution ends, who bears the cost of transfers or renewals, and how the certificate may be used in tenders. GRZAN reviews these clauses as part of registration support, because a technically flawless certificate with silent ownership terms can still strand a product in the market when the commercial relationship ends.

4. Practical recommendations

The recommendations below assume the certificate portfolio view described above: several certificates, several dates, one controlling calendar. They are deliberately administrative in character, because the obligations attached to the sanitary registration are administrative obligations with hard dates, and the penalties for missing them arrive through the market rather than through the review process. A calendar entry costs nothing to create and can prevent the loss of an entire certificate at renewal.

A final observation concerns the interaction of the two clocks. Because the enterprise annual review falls due every December 31 while each product certificate renews on its own five-year date, a portfolio held through a single importer accumulates a shared dependency on that importer’s compliance calendar. Distributors and manufacturers should align their contract review dates with the annual review cycle, so that any lapse is detected in the agreement cycle before it becomes a registration problem.

  1. Build a certificate calendar, with separate reminders for the five-year expiry date and for the December 31 annual milestone each year.
  2. Plan the renewal lead time at 3 months (practical estimate), covering document re-preparation and possible rounds of observations.
  3. Finalize the registration number printing scheme at the label design stage; do not wait for approval before changing the packaging.

5. Verification checklist

  • □ Confirm that the registration number prefix (DI or DN) matches the origin of the product
  • □ Confirm that the printing scheme for the registration number in a prominent position on the packaging has been finalized
  • □ Confirm the annual review status of the certificate-holding enterprise (as of December 31 of the current year)
  • □ Confirm that the five-year expiry date has been entered in the certificate calendar
  • □ Confirm that the ownership clause has been written into the distribution agreement (see article 31)

Regulatory information verified as of October 29, 2026.

GRZAN supports manufacturers, importers, and authorized representatives with medical device registration in Bolivia, covering dossier preparation, local entity coordination, and regulatory strategy. Contact info@grzanglobal.com for project inquiries.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail